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1. Introduction 
Osteoporosis is a disease of increased skeleton fragility accompanied by low BMD and 
microarchitectural deterioration. Osteoporosis and bone fragility result in significant 
morbidity and medical and social costs (Dennison et al., 2005; Cummings et al., 2002). The 
risk of fractures is greater among women with low BMD although it explains only part of 
the increased fracture tendency among the elderly (National Osteoporosis Foundation, 
1998).The diagnosis of osteoporosis is currently based on axial dual X-ray absorptiometry 
(DXA) measurements (National Osteoporosis Foundation 1998). In addition to being 
applicable for fracture prediction, axial DXA has a role in treatment monitoring protocols 
(Miller et al., 1996; Sowers et al., 1997). Furthermore, serial central DXA measurements have 
been used for research purposes to evaluate the risk- and preventive factors for 
postmenopausal bone loss (Burger et al., 1998; Hannan et al., 2000; Sirola et al., 2003) 
Perimenopausal bone loss rates of over -2 percent /year in spinal and over -1 percent /year 
in the femoral region have generally been reported (Harris and Dawson-Hughes, 1992; 
Pouilles et al., 1993; Pouilles et al., 1995; Prior et al., 1998; Ito et al., 1999).  In postmenopausal 
women, age related bone loss continues at age specific rate after the initial fastening during 
the menopausal transition (Hansen et al., 1995). 
There are two forms of vitamin D, ergocalciferol (vitamin D2) and cholecalciferol (vitamin 
D3). Cholecalciferol is the metabolically active form of vitamin D. Vitamin D is produced 
with either the effect of ultraviolet B radiation or ingested with nutrition and the 
metabolically active form is produced in the kidneys. It has been suggested that there might 
be a seasonal variation in bone turnover as assessed with both BMD and biochemical 
markers (Rosen et al., 1994.; Storm et al., 1998; Rapuri et al., 2002). The sun-light related 
vitamin D production which varies according to season seems to contribute to this 
phenomenon (Rapuri et al., 2002; Dawson-Hughes et al., 1997). However, other studies have 
not demonstrated any such effect as measured either by BMD or by levels of bone marker 
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compounds (Patel et al, 2001; Blumsohn et al., 2003). Consequently, the effect of the season 
when densitometry was performed on bone density is still unresolved. Furthermore, the role 
of a seasonal difference between two distant follow-up bone density measurements in 
postmenopausal bone loss has not been studied and thus, nothing is known about the effect of 
this phenomenon on treatment monitoring or other longitudinal data collection. If present, 
such seasonal variation could have significant effect on the evaluation of prospective data. 
The purpose of the present study was to investigate the effect of densitometry season on 
early postmenopausal BMD and bone loss in a subset of 954 Finnish women selected from 
the population-based Osteoporosis Risk Factor and Prevention (OSTPRE)-study. 
2. Subjects and methods 
2.1 Study population 
The study population was a randomly selected part of the prospective Kuopio Osteoporosis 
Risk Factor and Prevention (OSTPRE) study cohort. The OSTPRE cohort was established in 
1989 and included all women born in 1932-1941 and who were resident in Kuopio Province, 
Finland (n=14 220). A postal inquiry including questions about health disorders, 
medications including HRT, gynaecologic history, nutritional habits, physical activity, life-
style habits, and anthropometric information was sent to these women at baseline in 1989 
(Honkanen et al, 1991). The 5-year (in 1994 follow-up questionnaires were sent to the 13 100 
women who responded at baseline and responses were received from 11 954 at 5-year 
follow-up.  The study protocol has been approved by the ethics committee of University of 
Kuopio and Kuopio University Hospital. Informed written consent from the participants 
was collected with the postal inquiries. 
Of the 13 100 respondents in 1989, 11 055 (84.4 %) were willing to undergo DXA 
densitometry. A random sample of 2 362 women was selected for densitometry out of which 
2025 women actually underwent the procedure during 1989-91. The questionnaire 
information was updated at the time of bone densitometry. In all, 1 873 women underwent 
both baseline (1989-91) and follow-up (1994-97) measurements and 1 551 of these had valid 
serial measurements for both lumbar spine and femoral neck (excluding severe bone 
deformities, see section Bone mass measurements).  
For the present study, the following women were additionally excluded: 1) hysterectomized 
women (for whom it was impossible to define the menopausal status) and bilaterally 
ovariectomized women (n=445), 2) premenopausal women (n=152). Accordingly, the final 
study population consisted of 954 women (beginning of menopause either before or during 
follow-up) aged 48 to 59 years at baseline densitometry. The beginning of menopause was 
defined as 12 months’ amennorhea (WHO Scientific Group, 1996) and the duration of 
menopause varied from 1 to 26 years at follow-up densitometry. The duration of follow-up 
varied from 3.8 to 7.9 years (mean 5.8 years). 
2.2 Seasonal Difference Index (SDI) 
The study population was divided into three equal groups within the year according to month 
of measurement at baseline and follow-up: Group 1 (from January to April), Group 2 (from 
May to August) and Group 3 (from September to December). The basis for selecting these cut-
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offs was based on  the assumption that highest BMDs (reflecting serum vitamin D 
concentration) would be present at late summer and early fall season (within group 2) and the 
lowest at late winter (within group 3) whereas group 1 would present an intermediate. Also, in 
order to reveal the greatest differences in seasonal BMD variation between two successive 
measurements a numeric value of a Seasonal Difference Index (SDI) was calculated as follows:  
SDI = (Group number at baseline - Group number at follow-up) 
Accordingly, the numeric value of SDI varied from -2 to +2 (Table 1). In all, 521 (54.6 %)  
women were measured within the same season at both measurements (SDI group 0). In 212 
(22.2 %) women the follow-up measurement was carried out in a later season (SDI groups -1 
and -2) and in 221 (23.2 %) women in earlier season (SDI groups +1 and +2) than the 
baseline measurement. There was a significant variation in distribution of women into 
measurement seasons between and within baseline and follow-up measurements (Figure 1 ). 
Accordingly, any conclusions over differences between specific seasons were considered to 
be precluded due to this uneven distribution. 
 
Follow-up season (Group number)
Baseline season (Group number) January-April (1) May-August (2) September-December (3) 
January-April (1) 0 -1 -2 
May-August (2) 1  0 -1 
September-December (3) 2  1  0 
a) SDI=[Season Group at baseline]-[Season Group at follow-up] 
Table 1. Numeric values for the “Seasonal Difference Index” (SDI)a according to baseline 
and follow-up DXA measurement season 
2.3 Other variables 
2.3.1 Hormone therapy 
Women were divided into two groups according to their use of hormone therapy (HRT) 
(tablets and plasters) which was defined as the use of hormonal products for menopausal 
symptoms. HRT users (n=393) had used HRT continuously or occasionally during the 
follow-up regardless of whether or not they had used hormonal therapy before the baseline 
(14 women used HRT only before baseline, and were excluded in analysis on HRT effect). 
HRT non-users (n=547) had never used estrogen containing products aimed at 
postmenopausal therapy. In the OSTPRE cohort, the majority of HRT users were taking 
estrogen-progesterone combination products (56.2% of all HRT). No data was available on 
whether HRT was continuous or sequential. Forty-five percent of HRT users (occasional or 
continuous) had been treated with HRT also prior to baseline. The duration of HRT varied 
from one month to 7.5 years. The information about the use of hormonal products was 
obtained from the questionnaires. Comparison between self-reported use of HRT and the 
national prescription records of The Social Insurance Institution, Finland (KELA), for the 
whole OSTPRE cohort in 1996–2001 revealed that 97.8% of those who had received an 
oestrogen drug prescription reported HRT use in inquiries. On the other hand, in 25.5% of 
the self-reported non-users of HRT some oestrogen use (short-term, median 6.0 months) was 
recorded (Sirola et al., 2003a). 
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Fig. 1. Distribution of the study population accroding to DXA measurement month. 
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2.3.2 Adjusting variables 
The height and weight were measured with a stadiometer and calibrated scale by study 
group nurses at each bone densitometry. 
Nutritional calcium intake of each participant was estimated according to self-reported 
ingestion of milk products in postal inquiries. The following questions were asked:” How 
many deciliters of fluid milk products (milk, sour milk, yoghurt, etc.) do you consume daily? ” 
and ”How many slices of cheese do you eat daily?”. The amount of calcium was approximated 
to be 120 mg/dl for fluid milk products and 87 mg/slice for cheese (Sirola et al., 2003b). 
Women were divided into two categories (yes, no) according to the presence/absence of 
bone affecting diseases or medications at baseline. Bone affecting diseases/medications have 
been described previously by Kröger et al. (Kröger et al. 1994). Diseases were: renal disease, 
liver disease, insulin-dependent diabetes, malignancies, rheumatoid arthritis, endocrine 
abnormalities (parathyroid/thyroid glands, adrenals), malabsorption (including lactose 
malabsorption), total/partial gastrectomy, postovariectomy status, premenopausal 
amenorrhea, alcoholism and long-term immobilisation. Medications were: corticosteroids, 
diuretics, cytotoxic drugs, anticonvulsive drugs, anabolic steroids, calcitonin, 
bisphosphonates, vitamin D. 
Physical activity level was calculated based on combined physical activity in work and leisure 
based on self-reports in the postal inquiries. The physical activity was categorised into low, 
moderate and high (Kröger et al., 1994). 
2.4 Bone mass measurements 
The bone mineral density of lumbar spine (L2-L4) and left femoral neck was determined 
using the same dual X-ray absorptiometry (DXA) (Lunar DPX, Madison, Wisconsin, USA) 
equipment at both the baseline and five year measurements. The measurements were 
carried out in Kuopio University Hospital by specially trained personnel. The short term 
reproducibility of this method has been shown to be 0.9 % for lumbar spine and 1.5 % for 
femoral neck BMD measurements (Kröger et al., 1992).The long-term reproducibility 
(coefficient of variation) of the DXA instrument for BMD during the study period, as 
determined by regular phantom measurements, was 0.4 % (Komulainen et al., 1998). Each 
DXA measurement print was reviewed and women with bone deformities (osteoarthritis, 
osteophytes, scoliosis and compression fractures) in either area were excluded from the 
analyses. At the time of densitometry, also the weight and height of each participant was 
measured in a controlled situation. 
2.5 Statistical methods 
Statistical analyses were carried out with the Statistical Package for Social Sciences (SPSS) for 
Windows, version 17. The annual BMD changes for both measurement sites were calculated as 
follows: [(BMD at the 5-year follow-up - BMD at baseline) / duration of follow-up in years] 
and reported as percentage of baseline BMD. In categorical analyses, uni- and multivariate 
analysis of variance was used and Tukey (crude models) and Least Significant Difference 
(adjusted models) -post hoc tests were utilized to study differences between multiple groups 
when applicable. Adjustment for age, height, weight, months since menopause, mean calcium 
intake, use of HRT (no, occasional, continuous), physical activity level (low, moderate, high), 
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duration of follow-up (years) and the use of bone affecting medications or diseases (yes/no) 
(including vitamin D supplements) as covariates was performed.  
3. Results 
The baseline data revealed that there were no significant differences between the three 
season groups with respect to age, duration of menopause or HRT use (Table 2). There were 
no differences in the cross-sectional BMD between the season groups at baseline or at the 
five year follow-up (Table 2).   
In order to evaluate a possible contribution of seasonal differences to the follow-up BMD 
values, the association of SDI with mean annual bone loss was investigated (Figure 2). The 
bone loss rate in SDI categories -2 and 0 was greater than in SDI categories +1 and +2 
(p<0.01) in both lumbar and femoral regions (Figure 2). In lumbar spine, the difference in 
bone loss rate between SDI categories -1 and +1 was also significant (p=0.015). In femoral 
neck there was no significant difference between SDI category -1 and the other categories.  
These effects were independent of any adjustments.  
 
p-values refer to the differences of the respective SDI group in comparison to SDI 1 and 2 for lumbar spine 
(LS=full line) and femoral neck (FN=dotted line). a) adjusted for age, height, weight, months since menopause, 
calcium intake, use of HT (no, occasional, continuous), overall physical activity level (low, moderate, high), 
duration of follow-up (years) and use of bone affecting medications or diseases (yes/no) 
Fig. 2. Effect of Seasonal Difference Index (SDI) on mean annual bone loss rate (%) in early 
postmenopausal women (n=954). Analysis of covariancea 
 p < 0.001 (FN)  p < 0.001 (FN)
p < 0.01 (FN)
 p < 0.01 (LS) 
 p < 0.01 (LS) 
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Variable Group 1 Group 2 Group 3 Total 
  (n=424) (n=192) (n=338) (n=954) 
     
Means (SD) of continuous variables     
     
Duration of follow-up yrs 5,9(0,5) 5,8(0,4) 5,8(0,5) 5,8 (0,5) 
     
Duration of menopause, months  89,4(54,1) 86,2(48,1) 106,6(50,4) 95,0(52,3)d 
Baseline age, yrs 53,5(3,0) 53,5(2,9) 54,2(2,7) 53,7(2,9)d 
Baseline height, cm 160,9(5,1) 161,6(5,5) 160,8(5,3) 161,0(5,3) 
     
Baseline weight, kg  69,1(12,4) 68,6(11,4) 69,3(11,9) 69,1(12,0) 
Weight change (%) 2,9(5,2) 2,9(5,6) 3,0(5,3) 2,9(5,3) 
Grip strength, kPa 62,0(16,5) 62,2(15,6) 62,4(16,0) 62,2(16,1) 
Mean calcium intake, mg/day  789(343) 813(311) 799(319) 797(328) 
Baseline lumbar BMD, g/cm2 1,13(0,17) 1,13(0,16) 1,11(0,16) 1,12(0,16) 
Baseline femoral neck BMD, g/cm2 0,93(0,13) 0,93(0,13) 0,92(0,12) 0,92(0,13) 
FU lumbar BMD, g/cm2 1,07(0,17) 1,09(0,15) 1,07(0,16) 1,08(0,16) 
FU femoral neck BMD, g/cm2 0,88(0,12) 0,90(0,13) 0,89(0,12) 0,89(0,12) 
     
B. Distribution of category variables (%)     
Use of HRT during follow-up     
No use 55,8 56,0 64,7 59,0   c 
Occasional (<90 % of FU) 32,2 34,6 28,2 31,2 
Continuous (>90 % of FU) 12,1   9,4 7,2 9,8 
     
No bone affecting disease/medication 60,4 64,1 64,7 62,7 
Any previous fracture at baseline 20,9 23,3 20,6 21,3 
     
Previous wrist fracture at baseline 7,2 7,7 5,5 6,7 
Alcohol >1 drink/week 35,1 34,4 32,3 33,9 
Smoking 9,4 11,1 8,8 9,5 
High overall physical activity levelb 29,9 37,8 32,8 32,5 
a) Season Groups: Group 1 (from January to April), Group 2 (from May to August) and Group 3 (from September 
to December). b) Three categorical variable: low, moderate, high. c) p<0.05  /  d) p<0.001 
 
Table 2. Baseline characteristics of the study population according to season groupa (n=954 ). 
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Fig. 3. Effect of hormone therapy on lumbar spine (full line) and femoral neck (dotted line) 
bone loss according to seaosal difference index (SDI) category. Analysis  of variance 
(ANOVA, n=954). 
 p < 0.01  
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In ANOVA, SDI explained 2.3 percent (R2=0.023) and 1.3 percent (R2=0.013)  of the bone 
mass changes in lumbar spine and femoral neck, respectively. Furthermore, in linear 
regression models, SDI was positively associated with both lumbar spine and femoral neck 
bone loss (p<0.001) independent of all adjustments. 
In order to mimic the possible effect of SDI on a treatment monitoring protocol, we 
investigated the effects of HRT on bone loss according to SDI (Figure 3). HRT users had 
significantly lower bone loss rate in SDI categories -2 to 0 in comparison to HRT non-users 
(lumbar spine and femoral neck) (p<0.01). In SDI categories 1 to 2, there was no statistically 
significant difference between HRT users and non-users. These results were not affected by 
adjustments. 
4. Discussion 
The present study evaluated the effect of season on BMD and bone loss with a randomly 
selected population-based sample of 954 Finnish women. The seasonal difference between 
two successive axial DXA measurements, estimated with the “Seasonal Difference Index” 
(SDI), influenced the evaluation of postmenopausal bone loss rate. In addition, this factor 
interfered with the evaluation of protective bone effects of HRT. The exact direction of these 
relationships, in terms of specific seasons, was found to complex partly due to the study 
setting. 
The present study sample was large and randomly selected. There were few differences in 
the baseline variables between the three season groups. The DXA measurements were 
carried out with same equipment and measurement staff and all bone deformities were 
excluded. In addition, phantom calibration was performed regularly which should exclude 
any significant seasonal changes attributable to equipment performance. Furthermore, 
comprehensive adjustment for any potential confounders was used in the analyses. Hence, it 
is most unlikely that any major confounding could have occurred in the present study. 
Some weaknesses of the present study should also be considered. The follow-up time was 
relatively long with considerable inter-individual variation. Although the results were 
adjusted for duration of follow-up and reported in annual percent changes the follow-up 
period in treatment monitoring is usually only one or two years. However, the long follow-
up and large sample probably facilitated the detection of bone mass changes in the present 
study. Furthermore, the present study assumed that the pattern of bone loss between the 
approximately five-year follow-up was linear, masking any possible short-term non-linear 
patterns. However, adjusting for these changes would have required DXA measurement at 
the very least at 1 year intervals.  Lastly, the lack of information of serum vitamin D levels 
precluded causal conclusions. However, adjustment for bone affecting medication 
(including vitamin D containing products, medications and supplements) and calcium 
intake was performed eliminating bias due to these factors. 
The results of the present study have two major applications. Firstly, in treatment 
monitoring, an attempt should be made to measure bone density within the same season. 
Naturally, the seasonal limits depend on amount of seasonal variation in sunlight exposure 
of the study population and should be closely studied. The sub-division used in the present 
study provides one example in DXA measurements suitable for Scandinavian latitudes.  
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Secondly, in prospective studies, possible distortion in results due to seasonal differences in 
risk-factor analyses and treatment effects on bone loss rate should be closely considered. 
Accordingly, it could be worthwhile to create a “seasonal difference index” for each 
population based on the respective DXA measurement data. The effect of seasonal 
differences on densitometry-based risk-factors for postmenopausal bone loss remains to be 
resolved. It might be that seasonal dependency could interact with certain factors lessening 
their true impacts.  Also, the impact of these differences on fracture prediction remains to be 
resolved in future studies. 
The interpretation of seasonal indices needs to be undertaken with caution. In the present 
study, the differences between the SDI categories do not necessarily provide information of 
the exact season that each participant was measured (e.g. SDI +1 could represent a 
difference between baseline season category 3 and a 5-year season category 2 or a baseline 
category 2 and a 5-year category 1). Also, the baseline and follow-up season groups (groups 
1, 2, 3) itself included quite heterogeneous population. For example, the women measured 
during the first months of group 1 (January-February) were likely to have significantly 
lower BMDs in comparison to women presenting the other end (March-April) during which 
sun light exposure would be higher. We used this season categorisation order to categorize 
the measurement months into three equal groups within a year (i.e. four months per group: 
Spring (January-April), Summer (May-August) and Fall/Winter (September-December). 
This was based on the rapid changes in sun light exposure in the northern latitudes: sun 
light hours rapidly increase during may and decrease rapidly during september. 
Furthermore, the distribution of women into measurement months within each group was 
found to differ between baseline and follow-up densitometry. However, the goal of the 
present study was not to identify specific “risk seasons”, but only to assess variability in the 
estimated bone loss rate attributable to the seasons when the two successive measurements 
had been done. Thus, some arbitrary cut-offs, in terms of season groups, were forced to be 
decided. Accordingly, the hypothesis of high or low bone density according to sun exposure 
(and vitamin D levels) in baseline and follow-up was precluded by skew distribution of 
women into different measurement months. Before adaptation for wider use, these indices 
would need further testing and refinement in order to optimize the categorisation for local 
purposes.  
This is the first long-term population-based study investigating the contribution of seasonal 
difference between two successive DXA measurements on postmenopausal bone loss. 
Previous studies have shown significant alterations in vitamin D and PTH levels attributable 
to season  (Rapuri et al., 2002; Dawson-Hughes et al., 1997).which could also provide a 
pathophysiological mechanism for the seasonal bone effects. Some studies have also found 
seasonal variation in cross-sectional BMD data, bone markers and bone loss rate (Rosen et 
al., 1994.; Storm et al., 1998; Rapuri et al., 2002; Dawson-Hughes et al., 1997). However, other 
studies have failed to found any evidence on altered bone metabolism related to seasons as 
measured with either BMD or bone markers (Patel et al, 2001; Blumsohn et al., 2003). The 
ability to observe seasonal effects is likely to depend on geographical location. Another 
study conducted in northern latitudes (Gerdhem et al, 2004) failed to demonstrate any 
seasonal variation in cross-sectional study design  in Sweden. The present large study 
population, living at northern latitudes (latitude 63 degrees), might facilitate the detection of 
seasonal differences.  However, the present study also showed no significant cross-sectional 
variation in BMD. 
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The present study also attempted  to evaluate the possible bias in treatment monitoring 
resulting from seasonal difference via an investigation of how the SDI could affect the bone 
effect of HRT. In fact, variability in the protective effect of HRT between the SDI groups was 
detected. This serves as preliminary example of the extensiveness of the distortion in 
estimation of bone loss rate caused by seasonal difference. The inclusion of occasional use of 
HRT and less-than-perfect validity of HRT use in “non-users” probably mdified the results 
(Sirola et al., 2003a) but the trend was clear. Also, the effects may have been affected by lack 
of power due to small group sizes. However, seasonal densitometry difference may help in 
the identification of “non-responders” to HRT and be included in the list of other 
contributing factors (Sirola et al.,  2003c; Komulainen et al., 1999). Previously, it has been 
suggested that calcium may flatten the seasonal differences in bone loss rate among elderly 
women8 and that there might be seasonal variation in the bone response to vitamin D 
(Dawson-Hughes et al, 1991).  The present study also showed abolition in the difference in 
the bone loss rate between SDI categories in HRT users. 
In summary, seasonal differences should receive closer attention in treatment monitoring 
protocols and longitudinal risk factor studies. In future studies, the seasonal densitometry 
difference should be considered as a potential confounder and its effect on risk factor and 
treatment monitoring data should be assessed. In addition, factors that might lessen the 
seasonal changes in the bone loss rate, such as calcium, vitamin D and other bone drugs, 
should be identified. Our study raises, for the first time, the question of whether the results 
of longitudinal DXA measurements might be significantly distorted by seasonal differences 
especially in northern latitudes. 
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